Well, Geoman, maybe there is a glimmer of hope for us very, very longs in this. A new report that came out on January 10th 2018,about melanoma vaccines key market players still lists AVAX as one them. Here's the link:
Why would they include Avax on the list if it's dead for all intents and purposes? I think their strongest points against the big competitors are the statistically high survival rate and almost no side effects. Their weakest is not capitalizing on that. Good doctors and researchers do not always make good business people and it shows. Just saying, cause otherwise we get nothing from the company.
News 
Market Data 
Discover 
